Letters by company
Illumina, INC.
5 letters discussing ILMN. Everything written about it on this site is on its ticker page.
- Patient Capital Management 2Q26 Portfolio Activity & Attribution Opportunity Equity added Adyen, Global Payments, Genius Sports, Fidelity Wise Origin Bitcoin Fund and QXO preferred securities while exiting IBIT, Noble and Dave & Buster's. The strategy argues that depressed expectations create value in health care, payments, biotech and selected software, while retaining conviction in QXO's building-products consolidation strategy. second quarter of 2026 ADBE $90BADYEN $31BBIIB $33B
- Patient Capital Management 4Q25 Portfolio Activity and Attribution Patient Opportunity Equity added long-dated Biogen calls, initiated Fiserv and Chime, and exited Angi, arguing Biogen's Alzheimer’s franchise and pipeline offer upside while Fiserv can recover following a management reset. It backed Alphabet’s AI monetization, Precigen’s Papziemos launch, Illumina’s sequencing recovery, Coinbase’s platform expansion and Bitcoin’s scarcity. 4Q25 BIIB $33BCHYM $11BCOIN $47B
- Patient Capital Management 1Q25 Portfolio Activity and Attribution Patient Opportunity Equity Strategy added Carvana, New Fortress Energy and JD.com while selling Expand Energy and Green Thumb to concentrate on higher-conviction ideas. It argues that CVS’s Medicare Advantage pricing is improving, Chinese holdings are insulated by domestic revenue, and operational turnarounds support Carvana, Dave & Buster’s and Illumina. first quarter of 2025 BABA $270BCVNA $46BCVS $112B
- Patient Capital Management 2Q24 Portfolio Activity and Attribution Patient Opportunity Equity increased exposure to underfollowed health-care and smaller-company opportunities while finding several Magnificent 7 holdings closer to fair value. It entered Everi Holdings and exited Capital One and Uber. The portfolio argues that Illumina, Biogen and Royalty Pharma offer mispriced health-care upside, while Everi’s IGT transaction should create a stronger casino-technology platform. 2Q24 AMZN $2.7TBIIB $33BCOIN $47B
- Patient Capital Management 3Q24 Portfolio Activity and Attribution Patient Opportunity Equity added QXO and Dave & Buster’s, funded in part by exits from JPMorgan and Everi following its acquisition. The portfolio argues that QXO’s acquisition-led building-products strategy, Kosmos’s approaching cash-flow inflection, and Seadrill’s tightening deepwater-rig market offer idiosyncratic upside beyond macro conditions. 3Q24 BABA $270BET $70BEXPE $31B
